Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, randomized, placebo-controlled, two-part, single ascending dose study to evaluate the pharmacokinetics, pharmacodynamics and immunosuppressive activity of Lulizumab Pegol in healthy volunteers (SAD study)

Next Previous
X
Search
Trial Profile

A double blind, randomized, placebo-controlled, two-part, single ascending dose study to evaluate the pharmacokinetics, pharmacodynamics and immunosuppressive activity of Lulizumab Pegol in healthy volunteers (SAD study)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lulizumab pegol (Primary) ; Lulizumab pegol (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 22 Apr 2016 New trial record
    • 12 Mar 2016 Population pharmacokinetic/pharmacodynamic analysis (n=156) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top